TTRFAP Eligibility Page
EligibilityTo be eligible for a GLOBAL ASPIRE TTR amyloidosis award, applicants must
- Be within 5 years of receipt of a terminal degree (MD and/or PhD and/or PharmD or equivalent). Applicants enrolled in a residency, fellowship or postdoctoral program are encouraged to apply.
- Be affiliated with a host institution in developing Central/Eastern European countries, Latin America or Asia Pacific regions (excluding Japan, New Zealand and Australia); See FAQ’s for listing of eligible developing countries in Central/Eastern Europe.
- Have a mentor or senior investigator participate as a co-investigator.
Note: Members of the 2017 External Review Committee and 2016 ASPIRE awardees are not eligible to apply or serve as mentors or collaborating investigators on applications from other investigators on applications from eligible junior investigators.
Other FundingNo other government, non-governmental, or industry-sponsored projects may cover the same work scope as the grant application to the ASPIRE Program. However, a ASPIRE Program grant may be related to other funding from foundations or government agencies, as long as there is no direct overlap. It is the responsibility of the Applicant to justify the novelty of the proposal and provide evidence that the application does not overlap with any current or pending funding.
Once awarded, an ASPIRE grant cannot be amended upwards with additional funding support from Pfizer (via the standard IIR process or separate competitive grant program), nor can additional drug support above and beyond what is sufficient to complete the original study as reviewed and approved by the external review committee be provided. If supplemental funding is required, it must be secured from sources outside of Pfizer. Similarly, an ongoing Pfizer supported standard IIR cannot apply for supplemental funding via a Pfizer supported competitive grant program. ASPIRE awards cannot be provided to studies that are already in progress.
Criteria for Selection - Independent, External Review CommitteeThe ASPIRE applications will be reviewed by an independent, external review committee comprised of medical and scientific experts. All reviews will be conducted on a blinded basis. Applicant identifying information will be redacted from submissions as required to protect and ensure the integrity of the blinded review process. Grants will be awarded based upon:
- Scientific merit of the research proposal
- Qualifications of the applicant
- Relevance of proposed research to the program's mission
- Evidence of the applicant's commitment to an academic research career
- Evidence of a suitable research environment
Pfizer anticipates awarding up to 3 grants for the 2017 program.
Please note that Pfizer will perform an internal review of each submission to ensure it is within the scope of the program, and to verify that the principal investigator is cleared to conduct research (i.e. not appearing on any debarment list in countries where such lists exist).
QuestionsSee the Frequently Asked Questions (FAQ) for help.
You may also e-mail questions to questions.aspireresearch-TTR-Amyloidosis@pfizer.com